<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9667673</article-id><article-id pub-id-type="pmc">2150339</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>O'Byrne</surname><given-names>K. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Koukourakis</surname><given-names>M. I.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Saunders</surname><given-names>M. P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Salisbury</surname><given-names>A. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Isaacs</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Varcoe</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Taylor</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ganesan</surname><given-names>T. S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Harris</surname><given-names>A. L.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Talbot</surname><given-names>D. C.</given-names></name></contrib></contrib-group><aff>Imperial Cancer Research Fund Medical Oncology Unit, The Churchill, Oxford Radcliffe Hospital, UK.</aff><pub-date pub-type="ppub"><month>6</month><year>1998</year></pub-date><volume>77</volume><issue>11</issue><fpage>1950</fpage><lpage>1956</lpage><abstract><p>Bolus 5-fluorouracil (5-FU) is a phase-specific drug with a short plasma half-life that is used in combination with bolus cyclophosphamide and methotrexate in the treatment of breast cancer. The efficacy of 5-FU can be improved by continuous intravenous infusion using portable infusion pumps (infusional 5-FU). Infusional 5-FU, 200 mg m(-2) day(-1), in combination with standard doses of bolus cyclophosphamide and methotrexate, was evaluated in a phase I/II dose-finding study. The cyclophosphamide and methotrexate were administered in 28-day cycles as follows: cohort 1, cyclophosphamide 600 mg m(-2), days 1 and 8, and methotrexate 40 mg m(-2), day 1; cohort 2, cyclophosphamide 400 mg m(-2), days 1 and 8, and methotrexate 40 mg m(-2), day 1; cohort 3, cyclophosphamide 480 mg (m-2), days 1 and 8, and methotrexate 40 mg m(-2), day 1; cohort 4, cyclophosphamide 480 mg m(-2), days 1 and 8, and methotrexate 40 mg m(-2), days 1 and 8. Median overall survival was 10 months (range 3-21 months). Objective tumour responses were seen in 9 of 25 patients (36%, 95% CI 18-58%), including 3 of 13 patients (23%) previously treated for metastatic disease. Cohorts 1 and 4 proved to be too toxic, with five of six patients in cohort 1 and three of four in cohort 4 developing grade III/IV neutropenia. The dose intensity of cyclophosphamide achieved was as follows: cohort 1, 82%; cohort 2, 86%; cohort 3, 97%; cohort 4, 90%. Infusional 5-FU can be administered safely and is effective in combination with cyclophosphamide 480 mg m(-2), days 1 and 8, and methotrexate 40 mg m(-2), day 1, in the treatment of metastatic breast cancer.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00087-0242.tif" xlink:title="scanned-page" xlink:role="1950" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0243.tif" xlink:title="scanned-page" xlink:role="1951" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0244.tif" xlink:title="scanned-page" xlink:role="1952" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0245.tif" xlink:title="scanned-page" xlink:role="1953" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0246.tif" xlink:title="scanned-page" xlink:role="1954" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0247.tif" xlink:title="scanned-page" xlink:role="1955" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00087-0248.tif" xlink:title="scanned-page" xlink:role="1956" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

